Active Immuno-oncology TherapyOBI-833 is a second generation Globo H-based active immunotherapy. Its safety has been concluded in a Phase I dose escalation study. The dose and indication of OBI-833 to be used in the cohort expansion phase will be determined.
OBI-834, a new chemical entity to be used in a First-in-Human trial, will first be evaluated for its safety in healthy volunteers. The safety dose will be determined and applied to cancer patients for further evaluation of its efficacy.